Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias.

Author information

Affiliations

  • 1. Department of Neurology, Radboud University Medical Centre, and Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands; Radboud Alzheimer Centre, Nijmegen, The Netherlands; Department of Laboratory Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands.
      Authors
    • Herbert MK 1
    • Kuiperij HB 1
    • Verbeek MM 1
    (3 authors)
  • 2. Department of Neurology, Radboud University Medical Centre, and Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands.
      Authors
    • Aerts MB 2
    • Esselink RAJ 2
    • Bloem BR 2
    (3 authors)
  • 3. Department of Neurology, Radboud University Medical Centre, and Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands; Department of Geriatrics, Radboud University Medical Centre, Nijmegen, The Netherlands.
      Authors
    • Claassen JAHR 3
    (1 author)
  • 4. Radboud Alzheimer Centre, Nijmegen, The Netherlands; Department of Geriatrics, Radboud University Medical Centre, Nijmegen, The Netherlands.
      Authors
    • Spies PE 4
    (1 author)

ORCIDs linked to this article

Alzheimer's & Dementia : the Journal of the Alzheimer's Association, 13 Nov 2013, 10(4):448-455.e2
https://doi.org/10.1016/j.jalz.2013.05.1775 PMID: 24239248 

Abstract 

Background

Overlapping clinical features make it difficult to distinguish dementia with Lewy bodies (DLB) from Alzheimer's disease (AD) and other dementia types. In this study we aimed to determine whether the combination of cerebrospinal fluid (CSF) biomarkers, amyloid-β42 (Aβ42), total tau protein (t-tau), and phosphorylated tau protein (p-tau), in combination with 3-methoxy-4-hydroxyphenylethyleneglycol (MHPG), could be useful in discriminating DLB from vascular dementia (VaD) and frontotemporal dementia (FTD), as we previously demonstrated for differentiation of DLB from AD.

Methods

We retrospectively analyzed concentrations of MHPG, Aβ42, t-tau, and p-tau in CSF in patients with DLB, AD, VaD, and FTD. Using previously developed multivariate logistic regression models we assessed the diagnostic value of these CSF parameters.

Results

The currently used combination of Aβ42, t-tau, and p-tau yielded a sensitivity of 61.9% and a specificity of 91.7% for the discrimination between DLB and AD, but could not discriminate between DLB and VaD or FTD. The addition of MHPG to Aβ42, t-tau, and p-tau improves the discrimination of DLB from AD, yielding a sensitivity of 65.1% and specificity of 100%, but could not distinguish DLB from other forms of dementia.

Conclusions

Our results confirm in a separate patient cohort that addition of MHPG to Aβ42, t-tau, and p-tau improves the discrimination of DLB from AD but not the differentiation of DLB from VaD or FTD.

Full text links 

Read article at publisher's site: https://doi.org/10.1016/j.jalz.2013.05.1775

References 

Articles referenced by this article (51)

Show 10 more references (10 of 51)

Citations & impact 

Impact metrics

13
Citations
Jump to Citations

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/1913521
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/1913521

Article citations

Go to all (13) article citations

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.

Funding 

Funders who supported this work.

Center for Translational Molecular Medicine (1)